# NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

Study · id `cardio:ct-nct05638867` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05638867](<https://clinicaltrials.gov/study/NCT05638867>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05638867

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3944 participants.

## Technical summary

Registry record NCT05638867. Randomized; single masking; primary purpose treatment. Start 2023-11-25 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3944 participants (planned count; ClinicalTrials.gov record NCT05638867, source copy `cardio:ctgov-nct05638867-2026-08-11`, retrieved 2026-10-26)
- Started: 2023-11-25 (actual) (ClinicalTrials.gov record NCT05638867, source copy `cardio:ctgov-nct05638867-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05638867, source copy `cardio:ctgov-nct05638867-2026-08-11`, retrieved 2026-10-26)
- Completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT05638867, source copy `cardio:ctgov-nct05638867-2026-08-11`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05638867, source copy `cardio:ctgov-nct05638867-2026-08-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05638867-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Aspirin + Clopidogrel + Rivaroxaban
- Intervention (Drug): Aspirin + Clopidogrel
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 507dc80807dce67e56ab7544f20bc87cf8e56933d4c20ea4f52995570373d658
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
